Published Online: Tuesday, July 1, 2008

The Centers for Medicare & Medicaid Services (CMS) has recognized the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium as a mandated reference for making coverage decisions on the use of drugs and biologics in cancer care.

The NCCN compendium will be used by CMS for its national coverage determinations and by intermediaries and carriers for their regional determinations. One important application will be guiding decisions about coverage for the use of drugs and biologics in oncology beyond the FDA-approved indication.

The NCCN is an alliance of 21 of the world?s leading cancer centers dedicated to promoting high-quality cancer care; its clinical oncology practice guidelines are used widely by patients, clinicians, and other health care decision makers.

Latest Articles
The Advisory Committee on Immunization Practices recently updated the recommended interval between the 13-valeant pneumococcal conjugate vaccine and the 23-valeant pneumococcal polysaccharide vaccine in low-risk elderly patients.
Driving under the influence of prescription drugs may be just as dangerous as driving under the influence of alcohol.
Retrospective drug utilization review programs can reduce potentially unsafe concomitant opioid and central nervous system (CNS) medication use.
Chlamydia, gonorrhea, and syphilis are on the rise for the first time since 2006, according to the US Centers for Disease Control and Prevention.
Latest Issues